B. General Experimental Procedures
Compound 4, 7 8, 11 were synthesized according to previous procedure 1 .
Synthesis of tert-butyl (2-(2-(2-((4,6-dichloro-1,3,5-triazin-2-yl) 
At 0 o C, N-Boc-2,2′-(ethylenedioxy)diethylamine (218.5 mg) and cynuric chloride (162.1 mg) were added together followed by DIPEA (306.5 uL) and stirred for 1 hr. Progress of reaction was monitored by TLC. After completion of reaction, the solvent was revomed under vacuum. The crude was taken to next step without further purification. Synthesis of tert-butyl (2-(2-(2-((4,6-bis(4-((S)-2-azido-3-(4-hydroxyphenyl) Synthesis of (2S,2'S)-1,1'-((6-((2-(2-(2-aminoethoxy)ethoxy)ethyl)amino)-1,3,5-triazine-2,4-diyl)bis(piperazine-4,1-diyl))bis (2-azido-3-(4-hydroxyphenyl) propan-1-one) (6) TFA:DCM (1:1, 10 mL) was added to crude 5 and stirred for 1.5 h. Progress of reaction was monitored by TLC. After completion of reaction, the solvent was removed. 
LRMS (ESI-
Under inert atmosphere 6 (680.24 mg) and 7 (223.1 mg) were dissolved in tBuOH:H 2 O (1:1, 5 mL), followed by CuSO 4 (44 mg) and Na ascorbate (139.46 mg). The reaction was stirred for 24 hrs at room temperature. The solvent was removed and the crude was purified by prep HPLC (280 mg, 32%). 13 C NMR (101 MHz, MeOD) δ 167. 03, 156.74, 156.52, 156.39, 148.46, 130.19, 125.67, 121.69, 117.68, 115.15, 114.79, 78.99, 69.96, 69.95, 68.54, 66.50, 60.55, 51.88, 44.90, 43.30, 41.69, 40.38, 39.26, 39.08, 37.61, 27.79, 27.38, 25.72, 24.87, 14.57, 13.75, 10.40, 10.23 
Synthesis of 10
Synthesis of tert-butyl (2-(2-(2-((4,6-bis(4-((2R,3R)-2-azido-3-methylpentanoyl) 
1 (645.48 mg), 8 (881.35 mg) and K 2 CO 3 (675.79 mg) were add together in DMSO (10 mL)and stirred at room temperature for 24h. . Progress of reaction was monitored by TLC. After completion of reaction, the solvent was removed. The crude was taken to next step without further purification. Synthesis of (2R,2'R,3R,3'R)-1,1'-((6-((2-(2-(2-aminoethoxy)ethoxy)ethyl)amino)-1,3,5-triazine-2,4-diyl)bis(piperazine-4,1-diyl))bis(2-azido-3-methylpentan-1-one) (10) TFA:DCM (1:1, 10 mL) was added to crude 9 and stirred for 1.5 h. Progress of reaction was monitored by TLC. After completion of reaction, the solvent was removed.
LRMS (ESI+
LRMS (ESI+) m/z calcd for C 29 H 51 N 15 O 4 (M+H) + 674.4; found 674.4.
Under inert atmosphere 10 (771.73 mg) and 11 (452.3 mg) were dissolved in tBuOH:H 2 O (1:1, 5 mL), followed by CuSO 4 (57.5 mg) and Na ascorbate (184.24 mg). The reaction was stirred for 24 hrs at room temperature. The solvent was removed and the crude was purified by prep HPLC (560 mg, 55%). 88, 7.09, 7.07, 6.86, 6.84, 5.63, 5.60, 5.04, 5.02, 5.00, 4.06, 3.89, 3.74, 3.73, 3.71, 3.70, 3.68, 3.56, 3.34, 3.33, 3.33, 3.33, 3.32, 3.20, 3.19, 3.17, 3.15, 3.15, 3.13, 3.09, 3.07, 3.06, 3.04, 1.38 78, 169.04, 149.06, 143.47, 140.99, 134.31, 133.45, 130.90, 130.42, 129.89, 129.11, 127.29, 120.08, 119.28, 110.87, 101.17, 63.35, 53.40, 48.78, 40.84, 27.22, 24.61, 21.08 LRMS (ESI+) m/z calcd for C 49 H 63 N 4 O 8 S 2 + 899.4; found 900.6.
Synthesis of 2-((E)-2-((E)-4'-((2-(2-(2-((4,6-bis(4-((S)-2-(4-((1S,2S)-
BOP (22 mg), C (38 mg), D (30 mg) Et 3 N were added in 1 mL DMSO and stirred for 12 hr. After removal of DMSO. The crude was cooled on ice for 10 mins. TFA:DCM (1:1, 1 mL) was added to the mixture and stirred for 1 hr. Solvent was removed on vacuum and purified by reverse phase prep HPLC. (40 mg, 60%). 11, 168.45, 167.65, 162.80, 162.46, 162.11, 161.76, 155.88, 155.46, 153.79, 146.04, 144.08, 142.16, 141.98, 130.93, 129.71, 127.81, 127.19, 126.14, 124.39, 121.18, 118.27, 115.86, 115.36, 114.84, 112.78, 112.46, 110.79, 63.41, 62.75, 61.21, 53.51, 53.34, 51.76, 48.80, 43.33, 40.86, 39.91, 39.20, 37.53, 37.39, 28.88, 27.22, 26.12, 25.81, 25.45, 24.67, 22.33, 21.06, 14.60, 13.65, 10.59, 10.32 (2) BOP (21.67 mg) , 12 (86.32 mg), D (30 mg) Et 3 N (6.83 uL) were added in 1 mL DMSO and stirred for 12 hr. After removal of DMSO. The crude was cooled on ice for 10 mins. TFA:DCM (1:1, 1 mL) was added to the mixture and stirred for 1 hr. Solvent was removed on vacuum and purified by reverse phase prep HPLC (35 mg, 56%). 13 C NMR (101 MHz, D 2 O:CD 3 CN (7:3)) δ 168. 84, 167.56, 162.53, 162.18, 161.83, 161.48, 155.98, 155.66, 143.41, 141.92, 130.92, 129.60, 129.39, 128.02, 127.31, 126.56, 124.12, 121.21, 120.22, 115.75, 115.40, 112.49, 107.09, 70.10, 69.46, 68.78, 64.09, 63.50, 53.57, 53.44, 50.12, 49.43, 48.73, 44.04, 43.56, 40.60, 40.05, 37.92, 37.76, 27.37, 27.27, 27.03, 26.38, 24.44, 22.75, 21.19, 17.50, 14.95, 12.37, 10.26 
Synthesis of 2-((E)-2-((E)-4'-((2-(2-(2-((4,6-bis(4-((2R,3R)-2-(4-((S)-
1-amino-2-(4- hydroxyphenyl)ethyl)-1H-1,2,3-triazol-1-yl)-3-methylpentanoyl)piperazin-1-yl)-1,3,5- triazin-2-yl)amino)ethoxy)ethoxy)ethyl)carbamoyl)-6-(2-((E)-3,3-dimethyl-5-sulfonato-1-(3-(trimethylammonio)propyl)indolin-2-ylidene)ethylidene)-3,4,5,6-tetrahydro-[1,1'- biphenyl]-2-yl)vinyl)-3,3-dimethyl-1-(3-(trimethylammonio)propyl)-3H-indol-1-ium-5- sulfonateS17 2-((E)-2-((E)-4'-((2-(2-(2-((4,6-bis(4-((S)-2-(4-((1S,2S)-1-amino-2-methylbutyl)-1H- 1,2,3-triazol-1-yl)-3-(4-hydroxyphenyl)propanoyl)piperazin-1-yl)-1,3,5-triazin-2- yl)amino)ethoxy)ethoxy)ethyl)carbamoyl)-6-(2-((E)-3,3-dimethyl-5-sulfonato-1-(3- (trimethylammonio)propyl)indolin-2-ylidene)ethylidene)-3,4,5,6-tetrahydro-[1,1'- biphenyl]-2-yl)vinyl)-3,3-dimethyl-1-(3-(trimethylammonio)propyl)-3H-indol-1-ium-5- sulfonate (1)
